- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | BIODLINK-B (01875): CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025 | 7 | HKEx | ||
| 27.10. | BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia | 190 | PR Newswire | Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia [1].
This inaugural... ► Artikel lesen | |
| 16.10. | BIODLINK-B (01875): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CHANGE OF DIRECTORS, CHIEF EXECUTIVE OFFICER, AUTHORISED REPRESENTATIVE AND COMPOSITION OF ... | 1 | HKEx | ||
| 13.10. | BIODLINK-B (01875): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| BIODLINK INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 13.10. | BIODLINK-B (01875): CHANGE OF DIRECTORS, CHIEF EXECUTIVE OFFICER, AUTHORISED REPRESENTATIVE AND COMPOSITION OF BOARD COMMITTEE | 1 | HKEx | ||
| 26.09. | BIODLINK-B (01875): INTERIM REPORT 2025 | - | HKEx | ||
| 14.08. | BIODLINK-B (01875): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 14.08. | BIODLINK-B (01875): LETTER TO REGISTERED SHAREHOLDERS - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 12.08. | BIODLINK-B (01875): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| 31.07. | BIODLINK-B (01875): DATE OF BOARD MEETING | - | HKEx | ||
| 25.07. | TOT BIOPHARM-B (01875): AMENDED AND RESTATED ARTICLES OF ASSOCIATION | - | HKEx | ||
| 25.07. | TOT BIOPHARM-B (01875): CHANGE OF COMPANY ENGLISH NAME, AMENDMENTS TO THE ARTICLES OF ASSOCIATION, CHANGE OF STOCK SHORT NAME, CHANGE OF COMPANY WEBSITE ... | - | HKEx | ||
| 30.06. | TOT BIOPHARM-B (01875): TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE | - | HKEx | ||
| 21.03. | EQS Newswire: TOT BIOPHARM Turns a Profit for the First Time, Reports 2024 Net Income of RMB 34.8M | 461 | EQS Group (EN) | EQS Newswire / 21/03/2025 / 22:00 UTC+8
Guru Club, March 12 - TOT BIOPHARM - B (1875.HK) announced that for the full-year results ending December 31, 2024, the Company reported better-than-expected... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 275,73 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| ARCELLX | 65,51 | 0,00 % | Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset | ||
| NUVALENT | 104,83 | 0,00 % | Royalty-Pharma-Deal stützt Nuvalent: UBS bekräftigt Kaufempfehlung | ||
| STRUCTURE THERAPEUTICS | 71,33 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOME | 21,730 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| IMMUNOVANT | 26,760 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,310 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 83,53 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,370 | 0,00 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| COGENT BIOSCIENCES | 40,165 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 82,13 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| CG ONCOLOGY | 40,050 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 21,745 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,410 | 0,00 % | Dyne Therapeutics appoints Vikram Karnani to board of directors |
Das Unternehmen BIODLINK INTERNATIONAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODLINK INTERNATIONAL CO LTD finden Sie auf Wallstreet Online.